Who are 5-Azacitidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CEDAZURIDINE, decitabine injection, Azacitidine (AZA), Azacytidine, HAG Regimen, Azacitidine Injection, Decitabine and cedazuridine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/5-azacitidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

5-Azacitidine — Competitive Intelligence Brief

5-Azacitidine (5-Azacitidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hypomethylating agent. Area: Oncology.

phase 2 Hypomethylating agent DNA methyltransferase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

5-Azacitidine (5-Azacitidine) — Shirley Ryan AbilityLab. Inhibits DNA methyltransferase

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
5-Azacitidine TARGET	5-Azacitidine	Shirley Ryan AbilityLab	phase 2	Hypomethylating agent	DNA methyltransferase
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
decitabine injection	decitabine injection	Janssen Korea, Ltd., Korea	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacitidine (AZA)	Azacitidine (AZA)	Memorial Sloan Kettering Cancer Center	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacytidine, HAG Regimen	Azacytidine, HAG Regimen	Shenzhen Second People's Hospital	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Azacitidine Injection	Azacitidine Injection	Ascentage Pharma Group Inc.	marketed	DNA methyltransferase inhibitor	DNA methyltransferase (DNMT)
Decitabine and cedazuridine	Decitabine and cedazuridine	Race Oncology Ltd	marketed	Hypomethylating agent	DNA methyltransferase (DNMT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hypomethylating agent class)

AbbVie (prior sponsor, Abbott) · 1 drug in this class
Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Bio-Path Holdings, Inc. · 1 drug in this class
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias · 1 drug in this class
Otsuka Australia Pharmaceutical Pty Ltd · 1 drug in this class
Race Oncology Ltd · 1 drug in this class
Shirley Ryan AbilityLab · 1 drug in this class
Taiho Oncology, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 5-Azacitidine — Competitive Intelligence Brief. https://druglandscape.com/ci/5-azacitidine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab